Vol. 20/No. 10 | OncologyLive

How a NSCLC Pioneer Helped Unravel the Mysteries of EGFR

May 15, 2019

A 2018 Giants of Cancer Care award winner for Lung Cancer, Bruce E. Johnson, MD, has helped define the genomic era in lung cancer care. His notable contributions include characterizing the role that EGFR mutations play in non–small cell lung cancer.

Molecular Advances in Colorectal Cancer Are "Only the Tip of the Iceberg"

May 14, 2019

There has been a significant evolution in the care of patients with metastatic colorectal cancer over the past 20 years. However, this is only the tip of the iceberg and we are going to see more and more subgroups being defined and refined with many more rationally targeted agents matching these alterations.

Staging System for HPV-Related Oropharynx Cancer Paves Way for Change

May 13, 2019

A new staging system for head and neck cancers recognizes that patients with oropharyngeal malignancies associated with the human papillomavirus often have an excellent prognosis, but efforts to deintensify therapy for this population based on a fresh understanding of favorable risk factors may be premature.

Survival Gains Prompt Growing Emphasis on Fertility Preservation

May 13, 2019

Improved outcomes such as longer survival have increased interest among patients in pursuing fertility preservation options, and advances in techniques have made it possible for more patients to have children after treatment.

Bounty of New HCC Therapies Spurs Need for More Research

May 10, 2019

The optimal integration of new drugs into the treatment paradigm of HCC requires several key developments, including greater research into biomarkers that would help inform therapy choices, earlier treatment for patients diagnosed with HCC, and clinical trials that test combination strategies.

Early Trials Suggest New Path for CAR T-Cell Therapy in Solid Tumors

May 10, 2019

Two novel CAR T-cell therapies designed to attack solid tumors are showing signs of antitumor activity and tolerability in early clinical trial findings, fueling optimism about expanding this emerging form of immunotherapy beyond hematologic malignancies.

When the Quality of Evidence Just Doesn't Make the Grade in Cancer Care

May 10, 2019

The oncology clinical and research communities should demand that essential clinical trials and objectively valid evidence for efficacy and toxicity be obtained and reported before any regulatory agencies or national/international cancer societies support this strategy as a “standard of care” for cancer pain management.